newsfilter
← Latest News
GlobeNewswire·

Alimera Sciences Reports Second Quarter 2023 Results

Alimera Acquired U.S. Commercial Rights to YUTIQ®Landmark NEW DAY Study Completed Enrollment with over 300 PatientsConsolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022Global End User Demand